Bi-specific antibody | ApexOnco - Clinical Trials news and analysis

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

29 October 2024

GlycoMimetics gets on the PD-1/VEGF bandwagon

Regulatory

28 October 2024

Another PD-1/VEGF bispecific emerges

Conferences Trial results

24 October 2024

Triple meeting 2024 – Zai Lab impresses in small cell

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Trial results

16 October 2024

Roche says no to MAGE-A4... again

Regulatory

16 October 2024

Carvykti takes off

Meanwhile, Tecvayli stalls, but J&J still hopes for growth.

Data insights

14 October 2024

Genmab presses on with acasunlimab

Regulatory

2 October 2024

FDA red and green lights: September 2024

Regulatory Trial results

25 September 2024

Abecma’s first-line hopes dashed

Data insights

25 September 2024

Akeso builds up its ivonescimab ambitions again

Deals

24 September 2024

Context could herald what’s next for Nectin-4

Subscribe to Bi-specific antibody

GlycoMimetics gets on the PD-1/VEGF bandwagon

Another PD-1/VEGF bispecific emerges

Triple meeting 2024 – Zai Lab impresses in small cell

Roche says no to MAGE-A4... again

Carvykti takes off

Genmab presses on with acasunlimab

FDA red and green lights: September 2024

Abecma’s first-line hopes dashed

Akeso builds up its ivonescimab ambitions again

Context could herald what’s next for Nectin-4

Recent Quick take

Most Popular